DK3041476T3 - Corticosteroid, der indeholder oralt disintegrerende tabletsammensætninger til eosinofil øsofagit - Google Patents

Corticosteroid, der indeholder oralt disintegrerende tabletsammensætninger til eosinofil øsofagit Download PDF

Info

Publication number
DK3041476T3
DK3041476T3 DK14842811.3T DK14842811T DK3041476T3 DK 3041476 T3 DK3041476 T3 DK 3041476T3 DK 14842811 T DK14842811 T DK 14842811T DK 3041476 T3 DK3041476 T3 DK 3041476T3
Authority
DK
Denmark
Prior art keywords
isophagit
eosinophyl
oral disintegrating
containing oral
corticosteroid containing
Prior art date
Application number
DK14842811.3T
Other languages
English (en)
Inventor
Michael A Gosselin
Jin-Wang Lai
Gopi M Venkatesh
Original Assignee
Adare Pharmaceuticals Us L P
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52628945&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK3041476(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Adare Pharmaceuticals Us L P filed Critical Adare Pharmaceuticals Us L P
Application granted granted Critical
Publication of DK3041476T3 publication Critical patent/DK3041476T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
    • A61J3/10—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of compressed tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
    • B29C—SHAPING OR JOINING OF PLASTICS; SHAPING OF MATERIAL IN A PLASTIC STATE, NOT OTHERWISE PROVIDED FOR; AFTER-TREATMENT OF THE SHAPED PRODUCTS, e.g. REPAIRING
    • B29C43/00—Compression moulding, i.e. applying external pressure to flow the moulding material; Apparatus therefor
    • B29C43/003—Compression moulding, i.e. applying external pressure to flow the moulding material; Apparatus therefor characterised by the choice of material
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
    • B29C—SHAPING OR JOINING OF PLASTICS; SHAPING OF MATERIAL IN A PLASTIC STATE, NOT OTHERWISE PROVIDED FOR; AFTER-TREATMENT OF THE SHAPED PRODUCTS, e.g. REPAIRING
    • B29C43/00—Compression moulding, i.e. applying external pressure to flow the moulding material; Apparatus therefor
    • B29C43/006—Pressing and sintering powders, granules or fibres

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Mechanical Engineering (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Biophysics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK14842811.3T 2013-09-06 2014-09-05 Corticosteroid, der indeholder oralt disintegrerende tabletsammensætninger til eosinofil øsofagit DK3041476T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361874450P 2013-09-06 2013-09-06
PCT/US2014/054203 WO2015035114A1 (en) 2013-09-06 2014-09-05 Corticosteroid containing orally disintegrating tablet compositions for eosinophilic esophagitis

Publications (1)

Publication Number Publication Date
DK3041476T3 true DK3041476T3 (da) 2020-01-27

Family

ID=52628945

Family Applications (1)

Application Number Title Priority Date Filing Date
DK14842811.3T DK3041476T3 (da) 2013-09-06 2014-09-05 Corticosteroid, der indeholder oralt disintegrerende tabletsammensætninger til eosinofil øsofagit

Country Status (30)

Country Link
US (7) US10471071B2 (da)
EP (2) EP3041476B2 (da)
JP (1) JP6514702B2 (da)
KR (3) KR102609926B1 (da)
CN (1) CN105722513B (da)
AU (1) AU2014315110B2 (da)
BR (1) BR112016004844B1 (da)
CA (2) CA3089453A1 (da)
CL (1) CL2016000510A1 (da)
CY (1) CY1122626T1 (da)
DK (1) DK3041476T3 (da)
ES (1) ES2764849T5 (da)
GE (1) GEP20186820B (da)
HR (1) HRP20200015T1 (da)
HU (1) HUE048533T2 (da)
IL (4) IL318224A (da)
LT (1) LT3041476T (da)
MX (1) MX372770B (da)
MY (1) MY179870A (da)
PL (1) PL3041476T3 (da)
PT (1) PT3041476T (da)
RS (1) RS59803B1 (da)
RU (2) RU2678695C2 (da)
SA (1) SA516370678B1 (da)
SG (2) SG10201901677YA (da)
SI (1) SI3041476T1 (da)
SM (1) SMT202000039T1 (da)
UA (1) UA119969C2 (da)
WO (2) WO2015034678A2 (da)
ZA (1) ZA201702906B (da)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ624922A (en) 2009-10-01 2016-05-27 Adare Pharmaceuticals Inc Orally administered corticosteroid compositions
WO2015034678A2 (en) 2013-09-06 2015-03-12 Aptalis Pharmatech, Inc. Corticosteroid containing orally disintegrating tablet compositions for eosinophilic esophagitis
AU2016241369A1 (en) * 2015-04-01 2017-11-02 Lupin Atlantis Holdings Sa Process for manufacturing dry powder blends
WO2017217494A1 (ja) * 2016-06-16 2017-12-21 東和薬品株式会社 口腔内崩壊錠
TWI728172B (zh) 2016-08-18 2021-05-21 美商愛戴爾製藥股份有限公司 治療嗜伊紅性食道炎之方法
MX389336B (es) 2016-11-15 2025-03-20 Klaria Pharma Holding Ab Formulacion farmaceutica.
GB201709141D0 (en) 2017-06-08 2017-07-26 Klaria Pharma Holding Ab Pharmaceutical formulation
WO2019036483A1 (en) 2017-08-15 2019-02-21 Nephron Pharmaceuticals Corporation AQUEOUS NEBULIZATION COMPOSITION
DE102017127452A1 (de) * 2017-11-21 2019-05-23 Lts Lohmann Therapie-Systeme Ag Wasserlösliche Polymerklebschichten
GB201808462D0 (en) 2018-05-23 2018-07-11 Klaria Pharma Holding Ab Pharmaceutical formulation
CN113271979A (zh) 2018-10-24 2021-08-17 费灵有限公司 皮质类固醇的粘膜粘附性药物组合物
JP7094563B2 (ja) * 2019-08-05 2022-07-04 学校法人松山大学 錠剤及びその製造方法並びに打錠用粉末
KR20230163118A (ko) 2022-05-23 2023-11-30 에스케이온 주식회사 이차전지용 건식 전극 시트 제조방법 및 제조장치, 이차전지용 건식 전극 시트, 이차전지용 전극 및 이차전지
IT202300014295A1 (it) 2023-07-12 2025-01-12 Alfasigma Spa Composizioni orodispersibili comprendenti betametasone fosfato

Family Cites Families (116)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1170188A (en) 1967-09-15 1969-11-12 Bayer Ag N-trityl-imidazoles and salts and uses thereof
SE378109B (da) 1972-05-19 1975-08-18 Bofors Ab
DE2260384C3 (de) 1972-12-09 1979-11-29 Hoechst Ag, 6000 Frankfurt Oral zu applizierendes Corticosteroid-Präparat
US4080448A (en) 1974-11-13 1978-03-21 Mirsky Louis H Method of treating cellular stress
JPS56138200A (en) 1980-02-15 1981-10-28 Glaxo Group Ltd Androstane carbothioate compound
SE8004580L (sv) 1980-06-19 1981-12-20 Draco Ab Farmaceutisk beredning
ATE8790T1 (de) 1981-02-02 1984-08-15 Schering Corporation Aromatische heterocyclische steroidester, verfahren zu ihrer herstellung und pharmazeutische zusammensetzungen, die sie enthalten.
GB8630913D0 (en) 1986-12-24 1987-02-04 Glaxo Group Ltd Pharmaceutical compositions
US5446070A (en) 1991-02-27 1995-08-29 Nover Pharmaceuticals, Inc. Compositions and methods for topical administration of pharmaceutically active agents
ZA892859B (en) 1988-04-22 1989-12-27 Advanced Polymer Systems Inc Porous particles in preparations involving immiscible phases
US5278175A (en) 1990-02-02 1994-01-11 Pfizer Inc. Triazole antifungal agents
GB9002375D0 (en) 1990-02-02 1990-04-04 Pfizer Ltd Triazole antifungal agents
GR1001529B (el) 1990-09-07 1994-03-31 Elmuquimica Farm Sl Μέ?οδος για την λήψη νέων 21-εστέρων της 16-17-ακετάλης της πρ να-1,4-διενο-3,20-διόνης.
CA2101773A1 (en) 1991-01-31 1992-08-01 Toyoichi Tanaka Interpenetrating-polymer network phase-transition gels
US5252337A (en) 1991-06-25 1993-10-12 Eurand America, Inc. Controlled release calcium channel blocker microcapsules
CA2178473C (en) 1993-12-20 2004-08-24 Tsi-Zong Tzou Flunisolide aerosol formulations
US5639475A (en) 1995-02-03 1997-06-17 Eurand America, Incorporated Effervescent microcapsules
SE9501384D0 (sv) 1995-04-13 1995-04-13 Astra Ab Process for the preparation of respirable particles
GB9517062D0 (en) 1995-08-18 1995-10-25 Scherer Ltd R P Pharmaceutical compositions
US5863910A (en) 1996-01-12 1999-01-26 Bolonick; Joel Treatment of chronic inflammatory disorders of the gastrointestinal tract
DE19606151C2 (de) 1996-02-20 1999-05-12 Losan Pharma Gmbh Ibuprofen-Brausezubereitung sowie Verfahren zur Herstellung derselben
US8071128B2 (en) 1996-06-14 2011-12-06 Kyowa Hakko Kirin Co., Ltd. Intrabuccally rapidly disintegrating tablet and a production method of the tablets
DK0914818T3 (da) 1996-06-14 2005-07-04 Kyowa Hakko Kogyo Kk Intraoralt hurtigt desintegrerbar tablet
HUP0000116A3 (en) 1996-10-01 2000-08-28 Stanford Res Inst Int Taste-masked microcapsule compositions and methods of manufacture
SE9604486D0 (sv) 1996-12-05 1996-12-05 Astra Ab Novel formulation
GB9707934D0 (en) 1997-04-18 1997-06-04 Danbiosyst Uk Improved delivery of drugs to mucosal surfaces
IT1291362B1 (it) 1997-05-13 1999-01-07 Vectorpharma Int Composizioni farmaceutiche multicomponente bifasiche contenenti sostanze atte a modificare la partizione dei principi attivi
RO118174B1 (ro) 1997-08-21 2003-03-28 Aventis Pharma Deutschland Gmbh Lac de unghii şi utilizarea acestuia
GB9722426D0 (en) 1997-10-23 1997-12-24 Univ London Pharmacy Controlled release formulations
CA2322315C (en) 1998-03-06 2008-09-16 Eurand International S.P.A. Fast disintegrating tablets
SE514128C2 (sv) 1998-03-17 2001-01-08 Pharmalink Ab Användning av en glukokortikoid för framställning av ett läkemedel för behandling av glomerulonefrit
FR2781156B1 (fr) 1998-07-20 2001-06-29 Lafon Labor Composition pharmaceutique destinee notamment a la prevention et au traitement des radiomucites et des chimiomucites
US6596298B2 (en) 1998-09-25 2003-07-22 Warner-Lambert Company Fast dissolving orally comsumable films
GB9901819D0 (en) 1999-01-27 1999-03-17 Scherer Corp R P Pharmaceutical compositions
PL199123B1 (pl) 1999-04-23 2008-08-29 Leo Pharm Prod Ltd Niewodna kompozycja farmaceutyczna do stosowania naskórnego i jej zastosowanie
AU7026800A (en) 1999-09-11 2001-04-17 Glaxo Group Limited Pharmaceutical formulation of fluticasone propionate
WO2001039749A2 (en) 1999-11-30 2001-06-07 Panacea Biotec Limited Fast dissolving composition with prolonged sweet taste
AU2001279284A1 (en) 2000-07-05 2002-01-14 Capricorn Pharma, Inc Rapid-melt semi-solid compositions, methods of making same and methods of using same
KR100446101B1 (ko) 2000-12-07 2004-08-30 주식회사 삼양사 수난용성 약물의 서방성 제형 조성물
US6785841B2 (en) 2000-12-14 2004-08-31 International Business Machines Corporation Processor with redundant logic
US7125564B2 (en) 2001-02-16 2006-10-24 Lavipharm Laboratories, Inc. Water soluble and palatable complexes
US20030050312A1 (en) 2001-03-12 2003-03-13 Hjorth Thyge Borup Novel tablets and capsules and a process for its preparation
WO2002072150A2 (en) 2001-03-13 2002-09-19 Angiotech Pharmaceuticals Inc. Micellar drug delivery vehicles and uses thereof
US6872405B2 (en) 2001-05-10 2005-03-29 Yamanouchi Pharmaceutical Co., Ltd. Quick-disintegrating tablet in buccal cavity and manufacturing method thereof
MXPA03001838A (es) 2001-05-10 2003-09-10 Yamanouchi Pharmaceuticals Co Tabletas que se desintegran rapidamente en la cavidad bucal y proceso para producir las mismas.
US6656493B2 (en) 2001-07-30 2003-12-02 Wm. Wrigley Jr. Company Edible film formulations containing maltodextrin
FR2831820B1 (fr) * 2001-11-05 2004-08-20 Ethypharm Sa Comprime orodispersible presentant une grande homogeneite et son procede de preparation
US20030206978A1 (en) 2001-11-29 2003-11-06 Bob Sherwood Agglomerated particles including an active agent coprocessed with silicified microcrystalline cellulose
US20040009212A1 (en) 2002-01-30 2004-01-15 Pharma Power Biotec Co. Ltd. Mucoadhesive thermoresponsive medicament-carrier composition
JP4173670B2 (ja) 2002-03-08 2008-10-29 旭化成ファーマ株式会社 口腔内崩壊製剤
CN1290893C (zh) 2002-05-03 2006-12-20 詹森药业有限公司 聚合物微乳状液
AU2003270357A1 (en) 2002-09-06 2004-03-29 Microbia, Inc. Inhibitors of fungal invasion
WO2004023984A2 (en) 2002-09-13 2004-03-25 Smith C Steven Novel composition and method for treatment of upper respiratory conditions
US7731947B2 (en) 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
KR101099176B1 (ko) 2003-01-21 2011-12-27 니뽄 신야쿠 가부시키가이샤 구강내 속붕성 정제
JP2006516616A (ja) 2003-01-31 2006-07-06 オレクソ・アクチエボラゲット 即効薬剤組成物
US20040208833A1 (en) 2003-02-04 2004-10-21 Elan Pharma International Ltd. Novel fluticasone formulations
US8012505B2 (en) 2003-02-28 2011-09-06 Alk-Abello A/S Dosage form having a saccharide matrix
US20040265375A1 (en) * 2003-04-16 2004-12-30 Platteeuw Johannes J. Orally disintegrating tablets
US20050009848A1 (en) 2003-07-10 2005-01-13 Icn Pharmaceuticals Switzerland Ltd. Use of antivirals against inflammatory bowel diseases
US20060134054A1 (en) 2003-12-19 2006-06-22 Council Of Scientific And Industrial Research Polymer composition for pH dependent dissolution behavior and process for preparation thereof
BRPI0508612A (pt) 2004-03-10 2007-08-14 Schering Aktiengellschaft composições compreendendo drospirenona dispersa molecularmente
US8545881B2 (en) 2004-04-19 2013-10-01 Eurand Pharmaceuticals, Ltd. Orally disintegrating tablets and methods of manufacture
ATE353635T1 (de) * 2004-09-09 2007-03-15 Medinfar Produtos Farmaceutico Schnell wasserdispergierbare und domperidon enthaltende tabletten
US20060105038A1 (en) 2004-11-12 2006-05-18 Eurand Pharmaceuticals Limited Taste-masked pharmaceutical compositions prepared by coacervation
US20070020330A1 (en) 2004-11-24 2007-01-25 Medpointe Healthcare Inc. Compositions comprising azelastine and methods of use thereof
US20060292099A1 (en) 2005-05-25 2006-12-28 Michael Milburn Treatment of eye disorders with sirtuin modulators
TW200800142A (en) 2005-09-09 2008-01-01 Univ Manitoba Fast-disintegrating epinephrine tablets for buccal or sublingual administration
US8324192B2 (en) 2005-11-12 2012-12-04 The Regents Of The University Of California Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
US8497258B2 (en) 2005-11-12 2013-07-30 The Regents Of The University Of California Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
US8679545B2 (en) 2005-11-12 2014-03-25 The Regents Of The University Of California Topical corticosteroids for the treatment of inflammatory diseases of the gastrointestinal tract
JP2007158225A (ja) 2005-12-08 2007-06-21 Canon Inc 露光装置
CN1985799B (zh) 2005-12-19 2011-11-09 量子高科（北京）研究院有限公司 口腔崩解制剂的制备方法
JP2009521523A (ja) 2005-12-27 2009-06-04 ジュビラント・オルガノシス・リミテッド 口中溶解性医薬組成物およびその製造方法
US20080260655A1 (en) 2006-11-14 2008-10-23 Dov Tamarkin Substantially non-aqueous foamable petrolatum based pharmaceutical and cosmetic compositions and their uses
EP1958613A1 (en) 2007-02-15 2008-08-20 Polichem S.A. Dermal film-forming liquid formulations for drug release to skin
CA2721133C (en) 2007-04-13 2018-11-06 Somaxon Pharmaceuticals, Inc. Low-dose doxepin formulations and methods of making and using the same
EP2214679B1 (en) 2007-11-13 2019-03-27 Meritage Pharma, Inc. Corticosteroid compositions
US20100216754A1 (en) 2007-11-13 2010-08-26 Meritage Pharma, Inc. Compositions for the treatment of inflammation of the gastrointestinal tract
US20090123551A1 (en) 2007-11-13 2009-05-14 Meritage Pharma, Inc. Gastrointestinal delivery systems
US20150231156A1 (en) 2007-11-13 2015-08-20 Meritage Pharma, Inc. Corticosteroid compositions
US20090143343A1 (en) 2007-11-13 2009-06-04 Meritage Pharma, Inc. Compositions for the treatment of inflammation of the gastrointestinal tract
CA2708152A1 (en) 2007-12-10 2009-06-18 Eurand, Inc Orally disintegrating tablets comprising diphenhydramine
CN101925349A (zh) 2007-12-21 2010-12-22 欧兰德股份有限公司 替马西泮的口腔崩解片组合物
JP2009173552A (ja) 2008-01-21 2009-08-06 Lion Corp 胃腸薬
US20090264392A1 (en) 2008-04-21 2009-10-22 Meritage Pharma, Inc. Treating eosinophilic esophagitis
ES2358158T3 (es) 2008-07-21 2011-05-06 Dr. Falk Pharma Gmbh Formulación farmacéutica para el tratamiento del tracto digestivo superior.
CN102112114A (zh) 2008-08-08 2011-06-29 麦克内尔-Ppc股份有限公司 使用三氯蔗糖作为制粒剂
ES2811051T3 (es) 2008-08-20 2021-03-10 Univ California Corticosteroides para el tratamiento de enfermedades inflamatorias del tracto gastrointestinal
US8696568B2 (en) 2009-01-15 2014-04-15 Nestec S.A. Methods, system and kit for diagnosing and treating dysphagia
EP2398470A4 (en) 2009-02-23 2013-03-06 Aptalis Pharmatech Inc CONTROLLED RELEASE COMPOSITIONS COMPRISING A PROTON PUMP INHIBITOR
US20110097401A1 (en) * 2009-06-12 2011-04-28 Meritage Pharma, Inc. Methods for treating gastrointestinal disorders
US8348551B2 (en) * 2009-07-29 2013-01-08 Terratherm, Inc. Method and system for treating contaminated materials
CN102596237A (zh) 2009-09-07 2012-07-18 Dbv技术公司 治疗嗜酸细胞性食管炎的方法
NZ624922A (en) 2009-10-01 2016-05-27 Adare Pharmaceuticals Inc Orally administered corticosteroid compositions
BR112012012999A2 (pt) 2009-11-30 2019-04-02 Aptalis Pharmatech, Inc. Composição farmacêutica, e composição de tablete de desintegração oral (odt) outablete de dispersão rápida (rdt)
US20120164080A1 (en) 2010-06-24 2012-06-28 Meritage Pharma, Inc. Methods of treatment for esophageal inflammation
CA2819663C (en) 2010-12-02 2019-12-24 Adare Pharmaceuticals, Inc. Rapidly dispersing granules, orally disintegrating tablets and methods
WO2012097436A1 (en) 2011-01-18 2012-07-26 Toronto Rehabilitation Institute Method and device for swallowing impairment detection
SG191827A1 (en) 2011-01-28 2013-08-30 Nestec Sa Apparatuses and methods for diagnosing swallowing dysfunction
EP2790696A1 (en) 2011-12-16 2014-10-22 Atopix Therapeutics Limited Combination of crth2 antagonist and a proton pump inhibitor for the treatment of eosinophilic esophagitis
US20150209432A1 (en) 2012-07-26 2015-07-30 Lupin Limited Pharmaceutical compositions of proton pump inhibitor
TWI634900B (zh) 2013-07-11 2018-09-11 再生元醫藥公司 藉由投與ｉｌ－４ｒ抑制劑治療嗜酸性食道炎的方法
WO2015034678A2 (en) 2013-09-06 2015-03-12 Aptalis Pharmatech, Inc. Corticosteroid containing orally disintegrating tablet compositions for eosinophilic esophagitis
ES2716990T5 (es) 2013-12-23 2023-03-24 Dr Falk Pharma Gmbh Formulación farmacéutica optimizada para el tratamiento de cambios inflamatorios del esófago
US10294517B2 (en) 2014-03-17 2019-05-21 Children's Hospital Medical Center Genetic test for determining susceptibility for eosinophilic esophagitis
US10176301B2 (en) 2014-09-11 2019-01-08 Meritage Pharma, Inc. Systems, methods, and software for providing a patient-reported outcome measure of dysphagia patients with eosinophilic esophagitis
US9980975B2 (en) 2015-01-22 2018-05-29 Ems S.A. Dosage forms containing fluticasone propionate for the treatment of inflammatory conditions of the esophagus
US10869592B2 (en) 2015-02-23 2020-12-22 Uroviu Corp. Handheld surgical endoscope
KR102460040B1 (ko) 2016-04-27 2022-11-01 애브비 인코포레이티드 항-il-13 항체를 이용한 il-13 활성이 유해한 질환의 치료 방법
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions
TWI728172B (zh) 2016-08-18 2021-05-21 美商愛戴爾製藥股份有限公司 治療嗜伊紅性食道炎之方法
JP2021514513A (ja) 2018-02-21 2021-06-10 アデア ファーマシューティカルズ，ユーエス，エル．ピー． 好酸球性食道炎を管理する方法
KR20220074915A (ko) 2019-10-01 2022-06-03 엘로디 파마슈티컬스, 엘.피. 호산구성 식도염을 치료하고 칸디다증을 감소시키는 방법
WO2022020464A1 (en) 2020-07-21 2022-01-27 Ellodi Pharmaceuticals, L.P. Modified release rapidly disintegrating compositions of proton pump inhibitors
CA3215388A1 (en) 2021-04-20 2022-10-27 Gina EAGLE Methods of treating esophageal strictures

Also Published As

Publication number Publication date
IL305908B2 (en) 2025-06-01
RU2678695C2 (ru) 2019-01-31
EP3041476B1 (en) 2019-11-06
KR20160058829A (ko) 2016-05-25
JP6514702B2 (ja) 2019-05-15
SI3041476T1 (sl) 2020-03-31
RU2016112259A (ru) 2017-10-11
JP2016529314A (ja) 2016-09-23
SMT202000039T1 (it) 2020-03-13
US20160206627A1 (en) 2016-07-21
CL2016000510A1 (es) 2016-09-09
IL244419B (en) 2022-04-01
US20220110945A1 (en) 2022-04-14
SG10201901677YA (en) 2019-03-28
GEP20186820B (en) 2018-02-12
IL305908B1 (en) 2025-02-01
MX372770B (es) 2020-06-29
EP3041476A1 (en) 2016-07-13
EP3041476A4 (en) 2017-04-26
IL291562B1 (en) 2023-10-01
CY1122626T1 (el) 2021-03-12
CN105722513B (zh) 2021-10-22
RU2016112259A3 (da) 2018-05-16
WO2015035114A1 (en) 2015-03-12
US20260083754A1 (en) 2026-03-26
WO2015034678A2 (en) 2015-03-12
PL3041476T3 (pl) 2020-04-30
AU2014315110A1 (en) 2016-04-21
ES2764849T5 (es) 2023-05-31
WO2015034678A3 (en) 2015-07-30
RU2019100068A (ru) 2019-03-22
AU2014315110B2 (en) 2019-12-12
HUE048533T2 (hu) 2020-07-28
PT3041476T (pt) 2020-01-20
CA2923055C (en) 2020-09-15
RS59803B1 (sr) 2020-02-28
IL291562A (en) 2022-05-01
CA2923055A1 (en) 2015-03-12
BR112016004844A2 (da) 2017-08-01
ZA201702906B (en) 2018-12-19
KR102341165B1 (ko) 2021-12-20
KR20230169421A (ko) 2023-12-15
HRP20200015T1 (hr) 2020-03-20
EP3041476B2 (en) 2023-01-25
BR112016004844B1 (pt) 2022-04-26
HK1225974A1 (zh) 2017-09-22
KR102609926B1 (ko) 2023-12-05
MX2016002866A (es) 2016-10-26
US12447157B2 (en) 2025-10-21
SG11201601663XA (en) 2016-04-28
LT3041476T (lt) 2020-04-10
CN105722513A (zh) 2016-06-29
US11166961B2 (en) 2021-11-09
RU2019100068A3 (da) 2022-04-19
CA3089453A1 (en) 2015-03-12
US12310976B2 (en) 2025-05-27
UA119969C2 (uk) 2019-09-10
NZ718371A (en) 2021-03-26
IL318224A (en) 2025-03-01
US10471071B2 (en) 2019-11-12
EP3659587A1 (en) 2020-06-03
SA516370678B1 (ar) 2020-03-08
KR20210158858A (ko) 2021-12-31
US20250255884A1 (en) 2025-08-14
US20210205328A1 (en) 2021-07-08
US20200016171A1 (en) 2020-01-16
US20260027129A1 (en) 2026-01-29
US11260061B2 (en) 2022-03-01
IL244419A0 (en) 2016-04-21
MY179870A (en) 2020-11-18
IL291562B2 (en) 2024-02-01
IL305908A (en) 2023-11-01
ES2764849T3 (es) 2020-06-04

Similar Documents

Publication Publication Date Title
IL288961A (en) Pharmaceutical preparations
IL274024A (en) Oral preparations
DK3041476T3 (da) Corticosteroid, der indeholder oralt disintegrerende tabletsammensætninger til eosinofil øsofagit
DK3071203T3 (da) Tetrahydroquinolinsammensætninger som bet-bromdomæne-inhibitorer
PL3297605T3 (pl) Kompozycje farmaceutyczne do stosowania miejscowego
DK3043778T3 (da) Farmaceutiske sammensætninger, der indeholder refametinib
EP3488847C0 (en) SEMIFLUORINATED ALKANE COMPOSITIONS
LT2984166T (lt) Kompozicijos, skirtos mpsi gydymui
PL2943181T3 (pl) Kompozycje farmaceutyczne
ZA201408333B (en) Pharmaceutical compositions
LT3386991T (lt) Policikliniai junginiai, kaip brutono tirozinkinazės inhibitoriai
ZA201401683B (en) Pharmaceutical compositions for rectal administration
ZA201508677B (en) Stabilized mesembrine compositions
FR3004110B1 (fr) Composition pour lutter contre le stress
DK2998395T3 (da) Fremgangsmåde til fremstilling af lactaseholdige sammensætninger
ZA201505650B (en) New compositions
ZA201506637B (en) Micronized pharmaceutical compositions
DK2915526T3 (da) Farmaceutiske sammensætninger, der omfatter anagrelid
SG11201509114TA (en) Pharmaceutical compositions
DK3010552T3 (da) Sammensætninger til anvendelse i onkologi
LT3377044T (lt) Ibuprofeno kompozicijos, skirtos tiesioginiam peroraliniam įvedimui
GB201304699D0 (en) Pharmaceutical compositions
ITRM20130616A1 (it) Nuove composizioni.
ITRM20130618A1 (it) Nuove composizioni.
GB201321497D0 (en) Pharmaceutical compositions